Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q2869808> ?p ?o }
Showing triples 1 to 43 of
43
with 100 triples per page.
- Q2869808 subject Q6814466.
- Q2869808 subject Q8312632.
- Q2869808 subject Q8460853.
- Q2869808 subject Q8492054.
- Q2869808 abstract "Efavirenz/emtricitabine/tenofovir disoproxil, sold under the trade name Atripla among others, is a fixed-dose combination drug for the treatment of HIV infection. It combines tenofovir disoproxil, emtricitabine, and efavirenz into a fixed-dose pill. Combining the three drugs into a single, once-daily pill reduces pill burden and simplifies dosing schedules, and therefore has the potential to increase adherence to antiretroviral therapy.Atripla is the first multi-class antiretroviral drug available in the United States and represents the first collaboration between two U.S. pharmaceutical companies to combine their patented anti-HIV drugs into one product. The drug retails in the United States for US$1,850 for a one-month supply. An equivalent two pill regimen is available in developing countries at a price of about US$1.00 per day, as Gilead Sciences has licensed the patents covering emtricitabine/tenofovir to the Medicines Patent Pool and Merck and Co makes efavirenz available in developing countries at a reduced price. It was approved by the U.S. FDA on July 12, 2006. In the UK, the drug cost to the NHS is £626.90 per month as of March 2012.In adults, it is taken once daily on an empty stomach. Dosing at bedtime is recommended to improve tolerability of nervous system symptoms. Atripla is not recommended for patients under 18 years of age.In North America and Europe, Atripla is marketed jointly by Gilead Sciences and Bristol-Myers Squibb, but in much of the developing world, marketing and distribution is handled by Merck & Co.".
- Q2869808 atcPrefix "J05".
- Q2869808 atcSuffix "AR06".
- Q2869808 casNumber "731772-50-2".
- Q2869808 thumbnail Efavirenz,_emtricitabine_and_tenofovir_disoproxil.svg?width=300.
- Q2869808 wikiPageExternalLink atripla.com.
- Q2869808 wikiPageExternalLink atripla.html.
- Q2869808 wikiPageWikiLink Q1142055.
- Q2869808 wikiPageWikiLink Q155954.
- Q2869808 wikiPageWikiLink Q15787.
- Q2869808 wikiPageWikiLink Q17006726.
- Q2869808 wikiPageWikiLink Q1895998.
- Q2869808 wikiPageWikiLink Q204711.
- Q2869808 wikiPageWikiLink Q247489.
- Q2869808 wikiPageWikiLink Q266423.
- Q2869808 wikiPageWikiLink Q28734.
- Q2869808 wikiPageWikiLink Q28745.
- Q2869808 wikiPageWikiLink Q421559.
- Q2869808 wikiPageWikiLink Q422604.
- Q2869808 wikiPageWikiLink Q422645.
- Q2869808 wikiPageWikiLink Q5456317.
- Q2869808 wikiPageWikiLink Q663596.
- Q2869808 wikiPageWikiLink Q6814466.
- Q2869808 wikiPageWikiLink Q8312632.
- Q2869808 wikiPageWikiLink Q8460853.
- Q2869808 wikiPageWikiLink Q8492054.
- Q2869808 atcPrefix "J05".
- Q2869808 atcSuffix "AR06".
- Q2869808 casNumber "731772".
- Q2869808 drugName "Efavirenz/emtricitabine/tenofovir disoproxil".
- Q2869808 type ChemicalSubstance.
- Q2869808 type Drug.
- Q2869808 type ChemicalObject.
- Q2869808 type Thing.
- Q2869808 type Q8386.
- Q2869808 comment "Efavirenz/emtricitabine/tenofovir disoproxil, sold under the trade name Atripla among others, is a fixed-dose combination drug for the treatment of HIV infection. It combines tenofovir disoproxil, emtricitabine, and efavirenz into a fixed-dose pill.".
- Q2869808 label "Efavirenz/emtricitabine/tenofovir".
- Q2869808 depiction Efavirenz,_emtricitabine_and_tenofovir_disoproxil.svg.
- Q2869808 name "Efavirenz/emtricitabine/tenofovir disoproxil".